Ground-breaking development in Lund

The medical technology development company Vivoline® Medical tackles a complex problem in transplantation medicine. Lung transplantation is still a relatively minor occurrence with about 4,000 transplants per year worldwide. The need is much greater as over 300,000 people die annually from incurable lung diseases. Vivoline’s product shows great potential and can increase the number of transplants dramatically.

The product is unique. Vivoline LS1 allows for more lung transplants by assuring the quality of the donated lungs. Lungs that otherwise would be classed as unfit for transplantation can be reconditioned to a quality that meets the criteria for transplantation. Lives can be saved.

Yet another successful innovation from Lund
Vivoline LS1 is based on an innovation by the Lund University Professor Stig Steen, who also developed the principles behind the Lucas chest compression system, now implemented globally.
Professor Steen has a long history of developing innovations that have revolutionised their field. Depending on where it is implemented, Vivoline LS1 can increase the number of successful lung transplants by several hundred percent.
Yet another challenge can be solved using Vivoline LS1, as the status of the lung can be maintained for longer. This means that the donation base can be increased and the logistics chain managed more efficiently with better opportunities to match donated organs to the appropriate recipient. The overall outcome is better for everyone involved, not least the patients.

Taking innovations to market
It takes a lot of knowledge to develop an innovation, and even more to launch it on the market. It is therefore very difficult for individual researchers to enter the highly competitive global market, where demands on proof-of-concept are high.
Vivoline CEO Peter Sebelius has the experience and knowledge required to take innovations to market. He started his career in the Swedish Defense industry. Later on Peter accepted the challenging role as project leader for the Lucas chest compression system followed by other opportunities in the medtech sphere. Since 2009 Peter Sebelius is the CEO of Vivoline Medical.
“An important area for me is quality management, thus it is perhaps not surprising that high quality and good service are guiding lights in our company. Our employees have provided the knowledge and expertise necessary to bring this innovation to market, and they are the main contributors to our overall achievement and recent success”, he says.

Expected boost in lung transplantation
Vivoline has seen a tremendous development in the three years since Vivoline LS1 was first introduced. The product is used in clinics and research institutions in Sweden, Denmark, Norway, England, Ireland and North America, as well as a couple of clinics in Saudi Arabia and Australia.
There are only around 200 transplant centres in the world. The method and the technology behind Vivoline LS 1 are well known among clinicians. The first question is thus not how the system works; but rather how to make the investment possible.
Peter Sebelius makes a comparison with the developments in heart surgery over the last decades. “In 1969, the number of performed coronary artery bypass operations landed on a figure of around 5,000 in the USA. In 1996 the number of operations exceeded 600,000 in the U.S. alone, and I think a similar development is to be expected when it comes to lung transplantation”.
Vivoline is continuously conducting new ground-breaking research in close collaboration with Lund University, working towards the vision of a community where the vast majority of available donor organs will be utilised.

Life Science SNL 2014-1 - Affärstidningen Näringsliv

Näringsliv 2014-1

Huvudtema: Life Science
Medicon Valley – collaborating regionally to compete globally

Medicon Valley, the bi-national life science cluster spanning the island of Zealand in Eastern Denmark and the Skåne-region of Southern Sweden, is one of Europes most vibrant life science clusters with a large number of life science companies (pharma, biotech and medico) as well as research institutions located within a very small geographical area ...

Back to top